跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
617
首页
药物
617
617
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
New Compounds 617
申请人: ASTRAZENECA AB
优先权: 2007
US
Application of 212Pb-EB-PSMA-617 in prostate cancer
申请人: BEIJING SINOTAU PHARMACEUTICALS CO LTD
优先权: 2023
CN
COMBINATION THERAPIES WITH DNA DAMAGE RESPONSE INHIBITORS AND [ 177LU]LU-PSMA-617
申请人: NOVARTIS AG
优先权: 2024
WO
Application of pediococcus pentosaceus NHNK-617 in preparation of product for improving atherosclerosis and heart injury
申请人: QINGDAO NUOHE NUOKANG BIOTECHNOLOGY CO LTD
优先权: 2025
CN
A METHOD FOR RADIOLABELING PROCESS FOR THE PREPARATION OF PSMA-617 MOLECULE RADIOLABELED WITH [161TB]TB (TERBIUM-161)
申请人: CELAL BAYAR UENIVERSITESI DIGER MERKEZLER MUDURLUGU
优先权: 2023
WO
一种高效的前列腺特异性膜抗原配体PSMA-617的固相制备方法
申请人: 兰州大学
优先权: 2018
CN
Method and device for synthesizing prostate specific membrane antigen
申请人: ANHUI GUOPING PHARMACEUTICAL CO LTD
优先权: 2023
CN
Prostate-specific antigen targeting inhibitor of nuclide marker and preparation method of nuclide marker
申请人: BEIJING CANCER HOSPITAL
优先权: 2016
CN
药物
反馈